Differences in chamber structure contribute to the incidence of venous air trap chamber coagulation during AN69ST-CHF: clinical and in vitro evaluation

Table 1 Background of patients

	ACH-Σ group (8 patients/22 procedures)	Prismaflex group (11 patients/22 procedures)	p value
Age	63 (39, 77)	72 (63, 77)	0.41
Male/female	5/3	6/5	0.29
Sepsis% (patients)	75% (6)	81% (9)	0.72
APACHE II score	19 (10, 23)	19 (11.8, 23)	0.77
DIC score	4 (2, 6.3)	3 (1, 5)	0.31
White blood cell (10³/µl)	12.3 (7.3, 18.3)	12.6 (7.5, 15)	0.73
CRP (mg/dl)	16.1 (9.4, 20.0)	14.1 (5.3, 19.1)	0.50
PCT (ng/ml)	3.4 (1.4, 7.5)	3.6 (0.7, 12.6)	0.87
blood platelet (10⁴/uL)	7.4 (4.3, 13.4)	8 (6.3, 15.0)	0.23
PT (s)	14.4 (13.3, 15.7)	14.6 (13.6, 17.1)	0.20
APTT (s)	43 (35.3, 50.5)	46.2 (37.7, 51.0)	0.57
Fibrinogen (mg/dL)	325 (275, 455.8)	396 (274.8, 512)	0.34
FDP (ug/ml)	17.9 (11.8, 42.5)	14.6 (10.0, 25.9)	0.26
d-dimer (ug/ml)	12.9 (10.1, 24.9)	12.7 (6.4, 24.5)	0.35
TAT (ng/ml)	13.2 (6.0, 24.8)	6.4 (4.8, 19.4)	0.30

Presented data are based on electronical records and include the test results of blood samples drawn at 6:00 a.m. on the morning of the day CHF was performed. Data are expressed as median and interquartile range, and statistical analysis was performed by the Pearson’s chi-square test for gender, and also for sepsis, and by the Mann–Whitney U test for the other data
APACHE II score acute physiology and chronic health evaluation II score, DIC score disseminated intravascular coagulation score, CRP c-reactive protein, PCT procalcitonin, PT prothrombin time, APTT activated partial thromboplastin time, FDP fibrin degradation product, TAT thrombin–antithrombin complex

ISSN: 2059-1381